Objective: The purpose of the survey was to better understand the experiences of people who attempt antipsychotic discontinuation.
Method: A multiple-choice and short-answer survey was distributed in 2011-2012 to potential participants involved in participating organizations. Respondents were asked about past discontinuation events, including decision negotiation and withdrawal experience. This article thematically analyses their free-text responses.
Results: There were 98 valid surveys returned. Respondents highlighted the roles of the therapeutic alliance and health and illness explanatory models in understanding the context of discontinuation. Reported impacts of discontinuation were mixed and complex. Withdrawal syndromes were described by over half of the participants. Of the 98 respondents, 21 reported remaining antipsychotic-free at the time of survey completion.
Conclusions And Implications For Practice: Participant accounts highlight the importance of context and relationships in their thinking about antipsychotic discontinuation. Although results cannot necessarily be generalized, participant descriptions of withdrawal syndromes suggest there may be a need to improve education, monitoring, and support strategies for some people during discontinuation. Shifting toward a more collaborative, transparent, and service-user-driven approach to discontinuation may help to mitigate some of the negative discontinuation impacts identified. The polarized discontinuation outcomes described highlight the individuality of every participant's recovery journey and the need to avoid generalizing about the role of antipsychotics in care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1037/prj0000001 | DOI Listing |
Pharmazie
December 2024
Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan.
This study aimed to determine the risk of emergency admission by ambulance in patients taking potentially inappropriate medications (PIMs). We included 273,932 patients aged over 75 years of age admitted between January 1, 2019, and December 31, 2019, using the Japan Medical Data Center medical insurance database containing anonymized patient data. We excluded patients without a history of admission.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, USA.
Antibiotics have been well documented to result in several dermatological adverse reactions. Many of these adverse reactions are rashes that are difficult to distinguish. We present a case of a female patient in her 30s with acute generalised exanthematous pustulosis following vancomycin treatment for left breast cellulitis.
View Article and Find Full Text PDFJ Dermatolog Treat
December 2025
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Purpose: Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.
Material And Methods: This case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an initially successful treatment, the patient developed a rosacea-like dermatitis.
J Dermatolog Treat
December 2025
Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated. We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the real-world effectiveness and safety of IL inhibitors (IL-23, IL-17, IL-12/23) in 136 oncological patients with moderate-to-severe plaque psoriasis.
View Article and Find Full Text PDFAm J Ophthalmol
January 2025
the Wilmer Eye Institute, the Department of Ophthalmology, the Johns Hopkins University School of Medicine, Baltimore, MD, USA; the Department of Epidemiology, the Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address:
Purpose: To evaluate clinical and treatment outcomes in patients with peripheral ulcerative keratitis (PUK).
Design: Retrospective, case series SUBJECTS: Patients diagnosed with PUK at the Wilmer Eye Institute between January 2003 and October 2022.
Methods: Data collected included demographics, presence of systemic disease, disease laterality, duration of disease, PUK activity, presence of corneal perforation, and treatments.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!